Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Urovant Sciences GmbH

Home Clinical Trial Sponsors and OrganizationsUrovant Sciences GmbH

Urovant Sciences GmbH

Aeschengraben 27, Basel, Basel-Stadt, Switzerland

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

12

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

5

41.7%

Phase 2

4

33.3%

Phase 1

2

16.7%

Trial Status Distribution

Completed

9

75.0%

Recruiting

2

16.7%

Terminated

1

8.3%

Clinical Trials

Trials sponsored by this organization (12)

A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC

Oct 202285 participants

Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

Oct 2021403 participants

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

Dec 201980 participants

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

Sep 2019276 participants

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Mar 20191,105 participants

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

Dec 2018222 participants

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

Jun 2018506 participants

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

Mar 20181,530 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials12
Approvals
News

Back to Organizations